Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.

Zeming Mo,Jie Liu,Jinyan Zhang,Yaotiao Deng,Miao Xu,Yu Jiang

International immunopharmacology（2023）

引用 0|浏览6

暂无评分

摘要

Our study suggests that adjuvant toripalimab and pembrolizumab therapy have comparable efficacies in patients with AM and are both well tolerated. Adjuvant monotherapy with PD-1 inhibitors may not be appropriate for AM with NRAS mutations.

查看译文

关键词

acral melanoma,nras mutations,tertiary lymphoid structure formation,inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要